FDA approves Glenmark’s generic version of Novartis’ Exjade tablets for chronic iron overload
pharmafile | January 7, 2020 | News story | Manufacturing and Production, Research and Development | Glenmark, exjade, generic, pharma
Indian pharma firm Glenmark has announced it has secured approval from the FDA for its oral deferasirox tablets in the treatment of high iron levels in the body as a result of multiple blood infusions.
The therapy is a generic version of Novartis’ Exjade iron chelator tablets used in the treatment of chronic iron overload, a condition which can eventually lead to organ damage and potentially serious conditions such as heart disease and diabetes. In the 12 months ending in November last year, the therapy generated $106.4 million in sales for Novartis.
The approval covers the Mumbai-based firm’s 125mg, 250mg and 500mg tablet formulations. Glenmark’s share price elevated by around 1.37% with the reveal of the news.
Matt Fellows
Related Content
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …
Novartis acquires Chinook Therapeutics for $3.5bn
Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …